Home » Topics » BioWorld Science, Dermatologic

BioWorld Science, Dermatologic
RSS

Vallaurix presents MC1 receptor agonists

Nov. 15, 2016

Galectin Therapeutics looking for potential strategic partnership for GR-MD-02

Nov. 11, 2016

FDA clears IND for phase I/II trial of TWB-103 in split-thickness skin graft donor site wounds

Nov. 10, 2016

FDA approves Enbrel to treat children with moderate to severe plaque psoriasis

Nov. 7, 2016

Aclaris Therapeutics submits IND to begin study of ATI-50001

Nov. 4, 2016

MorphoSys and Leo Pharma collaborate to develop therapeutic antibodies in dermatology

Nov. 3, 2016

First-in-human dose administered in phase I clinical study of VB-1953

Nov. 2, 2016

Japan Tobacco and Torii sign license agreement for JTE-052 in Japan

Oct. 31, 2016

Bayer compares BAY-1003803 formulations in psoriasis plaque test

Oct. 27, 2016

AbbVie describes TRPV3 receptor antagonists

Oct. 24, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 27, 2026.
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
With improved technologies, biomarkers, failed drugs may come into their own
BioWorld
At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...